Journal
BLOOD
Volume 117, Issue 25, Pages 6866-6875Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-01-262535
Keywords
-
Categories
Funding
- Ministry of Education, Science, Sports, and Culture in Japan [20591137, 21010490, 20790678]
- Tokyo Biochemical Research Foundation, Tokyo, Japan
- Grants-in-Aid for Scientific Research [20790678, 09J10490, 20591137] Funding Source: KAKEN
Ask authors/readers for more resources
The activating mutations in JAK2 (including JAK2V617F) that have been described in patients with myeloproliferative neoplasms (MPNs) are linked directly to MPN pathogenesis. We developed R723, an orally bioavailable small molecule that inhibits JAK2 activity in vitro by 50% at a concentration of 2nM, while having minimal effects on JAK3, TYK2, and JAK1 activity. R723 inhibited cytokine-independent CFU-E growth and constitutive activation of STAT5 in primary hematopoietic cells expressing JAK2V617F. In an anemia mouse model induced by phenylhydrazine, R723 inhibited erythropoiesis. In a leukemia mouse model using Ba/F3 cells expressing JAK2V617F, R723 treatment prolonged survival and decreased tumor burden. In V617F-transgenic mice that closely mimic human primary myelofibrosis, R723 treatment improved survival, hepatosplenomegaly, leukocytosis, and thrombocytosis. R723 preferentially targeted the JAK2-dependent pathway rather than the JAK1- and JAK3-dependent pathways in vivo, and its effects on T and B lymphocytes were mild compared with its effects on myeloid cells. Our preclinical data indicate that R723 has a favorable safety profile and the potential to become an efficacious treatment for patients with JAK2V617F-positive MPNs. (Blood. 2011;117(25):6866-6875)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available